melphalan


Also found in: Thesaurus, Medical, Acronyms, Wikipedia.

melphalan

(ˈmɛlfəˌlæn)
n
(Pharmacology) a drug, C13H18Cl2N2O2, used to treat myeloid leukaemia
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.melphalan - antineoplastic drug (trade name Alkeran) used to treat multiple myeloma and some other malignanciesmelphalan - antineoplastic drug (trade name Alkeran) used to treat multiple myeloma and some other malignancies
antineoplastic, antineoplastic drug, cancer drug - any of several drugs that control or kill neoplastic cells; used in chemotherapy to kill cancer cells; all have unpleasant side effects that may include nausea and vomiting and hair loss and suppression of bone marrow function
Translations

melphalan

n melfalán m
References in periodicals archive ?
market exclusivity for its intravenous melphalan product after FDA approval of a marketing application, as well as access to clinical research grants and potential development program assistance through such means as the special protocol assessment.
In addition we are looking into other opportunities using the novel therapies in combination with melphalan and prednisone, and we expect to have results of our studies combining REVLIMID with melphalan-prednisone in the near future.
Our proprietary Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.
Oncopeptides is targeting multiple myeloma as a first indication with its lead compound, named melflufen which is a cytosuperior of the chemotherapeutic alkylator melphalan.
Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
In this report, we describe a case of primary AL amyloidosis in a young patient with isolated kidney involvement and rapid progression to ESRD, treated successfully with melphalan and ASCT.
In two small series, melphalan in combination with high-dose oral dexamethasone has also shown benefit.
The combination of melphalan and prednisone (MP) was once the standard of care for myeloma in Europe, but recent studies have shown the combination is greatly improved by the addition of the Novel Therapies: This positive opinion for thalidomide MP is based on a multi-center clinical trial showing average survival of more than 4 years, a year and a half more than MP without thalidomide.
In comparison, another group given melphalan and prednisone alone survived 33.
On the other hand, high-dose melphalan followed by stem cell rescue leads to CR rates of up to 60% and prolongs overall survival up to 7 years.
All patients also were treated with melphalan 200 mg/[m.